This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Jay Nelson Lozier, MD, PhD; Kenneth M. Brinkhous, MD

JAMA. 1994;271(1):47-51.

Abstract
Gene therapy for hemophilia A and B, now in the developmental stage, holds promise of a therapeutic revolution, resulting in amelioration or cure of the hemorrhagic diatheses. The genes for factor VIII and IX have been cloned, and vectors for the transfer of their cDNA into cells have been developed. Although viral and nonviral constructs containing the hemophilia gene have been used, most often modified retroviruses or adenoviruses have been employed. Cells that have been targeted for genetic modification to produce the antihemophilic proteins include hepatocytes, muscle cells, endothelial cells, keratinocytes, and fibroblasts. The delivery system may be (1) ex vivo, with implantation of modified cultured hemophilic cells in the donor, either in tissues or in semipermeable capsules, or (2) in vivo, the vector being delivered directly to target cells, genetically modifying them in situ. Successful in vivo therapy has been demonstrated in a hemophilic animal model, with conversion to a less severe hemophilic state.

(JAMA. 1994;271:47-51)

Author Affiliations
From the Departments of Medicine (Dr Lozier) and Pathology (Dr Brinkhous) and Center for Thrombosis and Hemostasis, University of North Carolina at Chapel Hill.

Footnotes
Reprint requests to University of North Carolina, Department of Medicine, CB# 7035, Chapel Hill, NC 27599 (Dr Lozier).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy
Mount et al.
Blood 2002;99:2670-2676.
ABSTRACT | FULL TEXT  

Adenovirus-Mediated Expression of Human Coagulation Factor IX in the Rhesus Macaque Is Associated With Dose-Limiting Toxicity
Lozier et al.
Blood 1999;94:3968-3975.
ABSTRACT | FULL TEXT  

Targeted Inactivation of the Coagulation Factor IX Gene Causes Hemophilia B in Mice
Kundu et al.
Blood 1998;92:168-174.
ABSTRACT | FULL TEXT  

Therapeutic Levels of Functional Human Factor X in Rats After Retroviral-Mediated Hepatic Gene Therapy
Le et al.
Blood 1997;89:1254-1259.
ABSTRACT | FULL TEXT  

Treatment for Hemophilia: Gene Therapy vs Transplantation
Fung and Lo
JAMA 1994;271:1575-1576.
ABSTRACT